MDS
60 programs · 58 companies
Programs
60
Companies
58
Trials
49
MOAs
39
CGRPantFGFRiBTKiTYK2iUSP1iFXIaiAnti-TauSHP2iCD3xCD20GLP-1/GIP
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Sotovorutinib | Approved | Aβ | ||
| LLY-1956 | Phase 1/2 | BCMA | ||
| Zanumavacamten | Phase 2/3 | TROP-2 | ||
| ARG-4339 | Phase 2 | BCL-2 | ||
| GMA-729 | Phase 2 | BCL-2 | ||
| SLR-4773 | Preclinical | SHP2 | ||
| ETN-5063 | Phase 1/2 | USP1 | ||
| Liraratamab | Phase 3 | SGLT2 | ||
| Zenotinib | Phase 2/3 | PD-L1 | ||
| Darasacituzumab | Phase 2/3 | IL-13 | ||
| Pexazanubrutinib | Preclinical | TROP-2 | ||
| MAY-IIT-361 | Preclinical | PARP | ||
| GEN-718 | Phase 1/2 | TROP-2 | ||
| Pexasotorasib | Phase 1 | IL-13 | ||
| SEP-123 | Phase 1/2 | RET | ||
| Kematenlimab | Phase 2/3 | CD3 | ||
| Teralemzoparlimab | Phase 2/3 | AuroraA | ||
| Kemaosocimab | Phase 3 | IL-17A | ||
| Tiramavacamten | Phase 2/3 | CD47 | ||
| Tiracilimab | Phase 1 | PLK4 | ||
| Nidasertib | Approved | CD38 | ||
| TUR-3071 | NDA/BLA | GIP-R | ||
| AAD-5814 | Phase 2 | BTK | ||
| Capisotorasib | Phase 1 | CD3 | ||
| Tixacagene | Preclinical | SMN2 | ||
| CLB-2823 | Phase 2 | IL-13 | ||
| OBS-1037 | Preclinical | MDM2 | ||
| Lirarelsin | Approved | GIP-R | ||
| Pemifutibatinib | Phase 3 | BET | ||
| Ivorasimod | Approved | PD-1 | ||
| VES-1701 | Phase 1 | IL-13 | ||
| Mirituximab | Phase 2 | FcRn | ||
| Rimanaritide | Phase 3 | CFTR | ||
| AMB-4811 | Preclinical | ALK | ||
| JAN-1547 | Approved | PLK4 | ||
| Nirarapivir | Phase 2 | FGFR | ||
| PLR-1516 | Phase 1 | Cl18.2 | ||
| Tiralucimab | NDA/BLA | CDK2 | ||
| TAI-4908 | Phase 3 | Menin | ||
| Cevinaritide | Preclinical | BTK | ||
| NOX-4885 | NDA/BLA | MET | ||
| OBS-1681 | Phase 3 | CD123 | ||
| BAY-6963 | Preclinical | CD3 | ||
| Kemanesiran | Phase 3 | KRASG12D | ||
| 416-1749 | Preclinical | HER2 | ||
| 416-6807 | Phase 2 | CD3 | ||
| Motaderotide | Phase 2 | C5 | ||
| IPC-884 | Approved | MET | ||
| Mavumavacamten | Phase 3 | DLL3 | ||
| AMO-1639 | Phase 2 | CD38 | ||
| ASP-8946 | Phase 1 | MET | ||
| CHI-IIT-594 | NDA/BLA | B7-H3 | ||
| Tezevorutinib | Phase 1/2 | RET | ||
| WAT-2618 | Preclinical | IL-17A | ||
| ZTS-7862 | Phase 1/2 | Menin | ||
| AMY-7405 | Phase 1/2 | GLP-1R | ||
| Gelirasimod | NDA/BLA | CD38 | ||
| EWT-919 | Preclinical | AuroraA | ||
| EWT-9686 | Phase 1 | TIGIT | ||
| ABB-7827 | NDA/BLA | SHP2 |
Trials (49)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT05137606 | Sotovorutinib | Approved | Active |
| NCT03952333 | LLY-1956 | Phase 1/2 | Completed |
| NCT03480272 | Zanumavacamten | Phase 2/3 | Terminated |
| NCT05906311 | ARG-4339 | Phase 2 | Terminated |
| NCT08330274 | Zenotinib | Phase 2/3 | Completed |
| NCT04396606 | Darasacituzumab | Phase 2/3 | Not yet recr... |
| NCT03318096 | MAY-IIT-361 | Preclinical | Active |
| NCT07079305 | GEN-718 | Phase 1/2 | Active |
| NCT04994874 | Pexasotorasib | Phase 1 | Active |
| NCT08228751 | SEP-123 | Phase 1/2 | Active |
| NCT04314608 | Kematenlimab | Phase 2/3 | Recruiting |
| NCT04588426 | Teralemzoparlimab | Phase 2/3 | Terminated |
| NCT04702623 | Tiracilimab | Phase 1 | Terminated |
| NCT03395165 | Nidasertib | Approved | Not yet recr... |
| NCT04115934 | Nidasertib | Approved | Terminated |
| NCT05606392 | AAD-5814 | Phase 2 | Completed |
| NCT06202992 | Tixacagene | Preclinical | Recruiting |
| NCT05398182 | CLB-2823 | Phase 2 | Completed |
| NCT04480281 | CLB-2823 | Phase 2 | Recruiting |
| NCT05526644 | Lirarelsin | Approved | Active |